Get started
Author

Andrea Bagaméri

Observed names: A Bagaméri, A. Bagameri, A. Bagaméri, Andrea Bagameri, Bagaméri, Andrea
Observed institutions: Universitair Ziekenhuis Leuven, Országos Idegsebészeti Tudományos Intézet, Hospital Universitario 12 De Octubre, National Institute of Oncology, Centre Hospitalier Universitaire de Liège, KU Leuven
ORCID: 0009-0007-5519-2598
Observed ORCID: 0009-0007-5519-2598
OpenAlex ID: A5039290487
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
2024 · Ignace Vergote, Antonio González-Martín, et al. · New England Journal of Medicine · 221
PDF
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
2025 · Alexander B Olawaiye, Laurence Gladieff, et al. · The Lancet · 76
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
2026 · Domenica Lorusso, Laurence Gladieff, et al. · The Lancet · 34
LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
2023 · I.B. Vergote, A. Gonzalez Martin, et al. · Annals of Oncology · 34
PDF
Chemotherapy With Or Without Pembrolizumab Followed By Maintenance With Olaparib Or Placebo For First-Line Treatment Of Advanced BRCA Non-Mutated Epithelial Ovarian Cancer: Results From The Randomized Phase 3 ENGOT-OV43/GOG-3036/KEYLYNK-001 Study
2025 · Ignace Vergote, David Cibula, et al. · International Journal of Gynecological Cancer · 30
PDF
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study
2025 · Ignace Vergote, Larry J. Copeland, et al. · European Journal of Cancer · 13
PDF
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer
2024 · Alexander B. Olawaiye, Jae-Weon Kim, et al. · Journal of Gynecologic Oncology · 12
PDF
Side-effects of paclitaxel therapy in ovarian cancer patents.
2001 · O Lehoczky, A Bagaméri, et al. · PubMed · 9
288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
2023 · K. Fujiwara, B.M. Slomovitz, et al. · Annals of Oncology · 6
PDF
[Does the addition of an anxiolytic drug improve the anti-emetic effectiveness of the steroid and granisetron combination in the prophylaxis of cisplatin-induced vomiting?].
2001 · O Lehoczky, A Bagaméri, et al. · PubMed · 6
#205 ROSELLA (GOG-3073, ENGOT-Ov72/MITO): a phase 3 study of relacorilant + nab-paclitaxel vs. nab-paclitaxel in advanced, platinum-resistant ovarian cancer
2023 · Domenica Lorusso, Andrea Bagameri, et al. · International Journal of Gynecological Cancer · 3
PDF
Does increasing the steroid dose enhance the efficacy of the antiemetic combination of granisetron and methylprednisolone in gynecologic cancer patients—a randomized study
2003 · Ottó Lehoczky, János Udvary, et al. · European Journal of Obstetrics & Gynecology and Reproductive Biology · 3
Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients
2002 · O. Lehoczky, Andrea Bagaméri, et al. · Journal of Obstetrics and Gynaecology · 3
[The treatment of ovarian cancer. Recommendation of the Hungarian Society of Gynaecologic Oncologists].
2022 · Zoltán Novák, Andrea Bagaméri, et al. · PubMed · 2
Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial
2026 · Ignace Vergote, David Cibula, et al. · The Lancet Oncology · 1
1071P Phase III, randomized, double-blind, placebo (Pbo)-controlled ENGOT-ov43/GOG-3036/KEYLYNK-001 study of 1L chemotherapy (CT) ± pembrolizumab (pembro) then maintenance (Maint) pembro ± olaparib (Ola) for advanced BRCA-nonmutated epithelial ovarian cancer (EOC): Analysis by HRD status
2025 · D. Cibula, K. Mcintyre, et al. · Annals of Oncology · 1
Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in second-line or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global, randomized, open-label, phase III study
2024 · Brian Slomovitz, Antonio González-Martín, et al. · Gynecologic Oncology · 1
237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer
2024 · Antonio Gonzalez Martín, Brian M. Slomovitz, et al. · International Journal of Gynecological Cancer · 1
TP019/#1387 Rosella (GOG-3073, ENGOT-OV72/MITO): a phase 3 study of relacorilant + nab paclitaxel vs. nab-paclitaxel in platinum-resistant ovarian cancer
2023 · Domenica Lorusso, Andrea Bagameri, et al. · International Journal of Gynecological Cancer · 1
PDF
[Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction].
2002 · Ottó Lehoczky, Andrea Bagaméri, et al. · PubMed · 1
[Early results of topotecan therapy in patients with recurrent ovarian cancer].
2002 · Ottó Lehoczky, Andrea Bagaméri, et al. · PubMed · 1
Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial
2025 · Alexander B. Olawaiye, Laurence Gladieff, et al. · Obstetrical & Gynecological Survey
InnovaTV 301/ENGOT-cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
2024 · Kosei Hasegawa, Brian M. Slomovitz, et al. · Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO)
PDF
832 The role of cytoreductive multivisceral surgery in ovarian growing teratoma syndrome – case series
2021 · E. Lukacs, Z. Novák, et al. · International Journal of Gynecological Cancer
PDF
[Results of docetaxel therapy in patients with relapsed ovarian cancer].
2005 · Ottó Lehoczky, László Thurzó, et al. · PubMed
Works count: 28
Citation count: 460
H-index: 8
I10-index: 7
Year
Topic
Type